

FY08 Q2: Non-GAAP Reconciliations

Worldwide Revenue Growth excluding the impact of Physio-Control, the divestitures of the Neuromodulation diagnostics product portfolio, and the Fidelis field action (in millions)	FY08 QTR 2	FY07 QTR 2	% Change
Worldwide Revenue, as reported	\$3,124	\$3,075	2%
Physio-Control revenue	(74)	(111)	(33)%
Divestitures of the Neuromodulation diagnostics product portfolio	-	(13)	NA
Fidelis field action	<u>130</u>	<u>-</u>	NA
Worldwide Revenue, adjusted	\$3,180	\$2,951	8%

Worldwide Neuromodulation Revenue Growth excluding the impact of the divestitures of the diagnostics product portfolio (in millions)	FY08 QTR 2	FY07 QTR 2	% Change
Neuromodulation Revenue, as reported	\$321	\$291	10%
Diagnostics product portfolio revenue	<u>-</u>	<u>(13)</u>	NA
Neuromodulation Revenue, adjusted	\$321	\$278	15%



Medtronic®